Category: basic life sciences retractions

Corrections (and one EoC) propagate for distinguished plant biologist, Olivier Voinnet

Olivier Voinnet
Olivier Voinnet

There may be some deeply rooted issues in the work of high-profile plant biologist Olivier Voinnet, biology department research director at ETH in Zurich. Corrections have continued to pile up months after his work was hit with a barrage of criticism on PubPeer. We’ve tracked a total of seven corrections over the past five months (not including the April retraction of a 2004 paper in The Plant Cell). One of the corrected papers also received an Expression of Concern this week.

Collectively, the corrected papers have accumulated more than 1200 citations.

In January, Voinnet said he planned to correct multiple papers, after receiving “an anonymous email.”

One of the recent corrections we found is for a 2003 article in The Plant Journal, “An enhanced transient expression system in plants based on suppression of gene silencing by the p19 protein of tomato bushy stunt virus,” which details using proteins from a tomato virus to help alter gene expression. The study has been cited 862 times, according to Thomson Scientific’s Web of Knowledge. Here’s the correction notice, posted June 8:

Continue reading Corrections (and one EoC) propagate for distinguished plant biologist, Olivier Voinnet

“Values were outside expected ranges”: Toxicology paper spiked after audit

Toxicological PathologyResearchers at the National Institute of Environmental Health Sciences have retracted a 2014 article after a review unearthed unresolved problems with the study’s control material.

The retracted paper, “Effect of Temperature and Storage Time on Sorbitol Dehydrogenase Activity in Sprague-Dawley Rat Serum and Plasma,” looked to test the durability and stability of sorbitol dehydrogenase, an enzyme used to detect cancerous liver damage in rats.

Here’s the complete retraction notice from Toxicologic Pathology :

Continue reading “Values were outside expected ranges”: Toxicology paper spiked after audit

JBC cancer paper felled by duplication is one author’s second retraction this month

25.coverA 2002 paper in the Journal of Biological Chemistry on how lung cancer cells resist death has been retracted for duplicating figures from a 2001 paper.

The retracted paper, “Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposide-induced apoptosis,” shares the first and last authors with the 2001 paper, in Oncogene, as well as two other co-authors.

Here’s JBC’s entire retraction note, a sub-genre with which we’ve become intimately familiar by now:

Continue reading JBC cancer paper felled by duplication is one author’s second retraction this month

Lost your data? Blame an earthquake

coverJNC

A natural disaster is to blame for a retraction about lethal brain tumors. At least, that’s where the authors say the problem started: with a 2010 earthquake that caused a loss of “substantial data.”

The paper, “Superoxide-dependent uptake of vitamin C in human glioma cells,” looks at how the cells of lethal brain tumors interact with the vitamin commonly used to reduce side effects of therapies.

Post earthquake, someone digitally filled in a western blot analysis of proteins from a cell line and rat brains, as a “temporary solution.” And then the temporary solution made its way into the Journal of Neurochemistry.

Here’s the retraction note from the journal, including an image of the sneaky western blot:

Continue reading Lost your data? Blame an earthquake

Oncogene to retract breast cancer paper following years-old misconduct investigation

Oncogene is retracting a 2010 paper on the molecular details of breast cancer cells as they undergo metastasis following an investigation that discovered the first author had committed misconduct.

The thing is, the investigation concluded in 2012, and the paper — “miR-661 expression in SNAI1-induced epithelial to mesenchymal transition contributes to breast cancer cell invasion by targeting Nectin-1 and StarD10 messengers” — isn’t being retracted until next week.

According to Lucinda Haines, senior publishing manager at Nature Publishing Group, the paper will be retracted June 29.

We heard from Iris Behrmann, Head of the Life Sciences Research Unit at the University of Luxembourg:

Continue reading Oncogene to retract breast cancer paper following years-old misconduct investigation

MacArthur awardee retracts signaling biology paper

A prominent biochemist and his co-author are pulling one of their papers in the Journal of Biological Chemistry because…well, we’re not sure.

That’s because the retraction note is – as we’ve come to expect from JBC – not very informative.

Here’s the only explanation for the retraction of “The Down Syndrome Cell Adhesion Molecule (DSCAM) Interacts with and Activates Pak”:

Continue reading MacArthur awardee retracts signaling biology paper

Columbia biologists “deeply regret” Nature retraction, after postdoc faked 74 panels in 3 papers

natureA team of Columbia University biologists has retracted a 2013 Nature paper on the molecular pathways underlying Alzheimer’s disease, the second retraction from the group after a postdoc faked data.

An April report from the Office of Research Integrity (ORI) found the a first author, former Columbia postdoc Ryousuke Fujita, responsible for “knowingly and intentionally fabricating and falsifying research in seventy-four (74) panels” in three papers: a 2011 Cell paper retracted in 2014, an unpublished manuscript, and this now-retracted Nature paper, “Integrative genomics identifies APOE e4 effectors in Alzheimer’s disease.”

The paper was touted in a Columbia University Medical Center press release as identifying “key molecular pathways” leading to late-onset Alzheimer’s disease. The paper fingered two potential molecular drug targets, as well.

Here is the full retraction notice: Continue reading Columbia biologists “deeply regret” Nature retraction, after postdoc faked 74 panels in 3 papers

High-profile aging paper posts old erratum, requested by author more than one year prior

GenomeBioGenome Biology has partially retracted a high-profile paper about an epigenetic biomarker of aging – a year and a half after the author alerted the journal to a software coding error that invalidated one of its findings.

The paper, “DNA methylation age of human tissues and cell types,” garnered some media coverage and forms the basis of its author Steve Horvath‘s work on measuring human aging. It has been cited 73 times, according to Thomson Scientific’s Web of Knowledge. The article is also recommended on the post-publication peer review site Faculty of 1000.

The lengthy, peer-reviewed erratum notice, written by Horvath, refers to several figures and files, as well as a conclusion:

Continue reading High-profile aging paper posts old erratum, requested by author more than one year prior

“Significant overlap” between figures spurs note of concern for 13-year-old retinoblastoma paper

AmJPatholThe American Journal of Pathology has posted a note of concern to a 2002 paper about retinoblastoma after discovering two sets of figures “share significant overlap… suggesting that they did not originate from different specimens.”

The overlap was “simultaneously brought to the attention of the Editors” by both the corresponding author and a “concerned reader.”

The paper examined the role of a transcription factor called NF-kappaB in driving retinoblastoma, and suggested that inhibiting the molecule’s activity could be a therapeutic strategy.

The authors attribute the overlap to “an inadvertent misidentification of the original files at the stage of image capture.” They add that they “sincerely regret this inadvertent error;” because other data in the paper show “concordant results,” they stand by the paper’s findings.

Here’s the note:

Continue reading “Significant overlap” between figures spurs note of concern for 13-year-old retinoblastoma paper

Nature retraction, resignation result after lung cancer cell lines “cannot be those specified”

cover_natureUpon realizing they had experienced a case of mistaken cell-line identity, the authors of a 2014 Nature paper on lung cancer think “it prudent to retract pending more thorough investigation,” as they explain in a notice published Wednesday.

The problem seems to stem from more than just honest error, according to corresponding author Julian Downward, a scientist at the Francis Crick Institute in the UK.

In a 1,215 word statement, sent to us via the Director of Research Communications and Engagement at Cancer Research UK, which funds Downward’s research, Downward told us the backstory not presented in the journal’s retraction note:

Continue reading Nature retraction, resignation result after lung cancer cell lines “cannot be those specified”